Drug Type Small molecule drug |
Synonyms Brimonidine/dorzolamide/timolol, Krytantek PF + [2] |
Mechanism ADRA2 agonists(Adrenergic receptors alpha-2 agonists), CAs inhibitors(Carbonic anhydrases inhibitors), β-adrenoceptors antagonists(Beta adrenergic receptors antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date MX (01 Sep 2007), |
Regulation- |
Molecular FormulaC15H16BrN5O6 |
InChIKeyQZHBYNSSDLTCRG-LREBCSMRSA-N |
CAS Registry70359-46-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Glaucoma | MX | 01 Sep 2007 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glaucoma, Open-Angle | Preclinical | - | 01 Apr 2016 |
Phase 1 | 24 | (PRO-122) | vwgfhjcthj(epjdaomzpl) = rhxmkfoigf bjljtnegal (ievnmhjvvp, ngaiysuaej - mjsgrrozqn) View more | - | 13 Dec 2019 | ||
(Krytantek Ofteno®) | vwgfhjcthj(epjdaomzpl) = fovtkoydse bjljtnegal (ievnmhjvvp, lbjkgvvodb - ynhlvwijzo) View more | ||||||
Not Applicable | 90 | (iugduvlqlm) = zbsqcvkplf pqwmrchbkl (isbjowhbmh ) View more | - | 19 Dec 2014 | |||
(iugduvlqlm) = kuxsxkckre pqwmrchbkl (isbjowhbmh ) View more |